Form 4: Dyne Therapeutics Chief Medical Officer Douglas Kerr Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 1,343 shares of common stock on March 5, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 5, 2025, Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, sold 1,343 shares of Dyne Therapeutics (DYN) common stock.
- The sale was executed at a weighted average price of $11.83 per share, with individual transactions ranging from $11.73 to $11.94.
- The sale was to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on December 4, 2024.
- Following the transaction, Kerr still beneficially owns 94,157 shares of Dyne Therapeutics, including 92,500 unvested RSUs.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 2024-12-04 | Date of restricted stock units grant |
| 2025-03-05 | Date of stock sale |
| 2025-03-07 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.